Destiny Pharma's XF-73 Being Studied For Diabetic Foot Ulcers, Burns Too

One year after its IPO, UK-based Destiny Pharma's CEO tells Scrip it's on track with US development of its lead antimicrobial asset XF-73 for prevention of post-operative infections and will also develop a new formulation to treat infections in diabetic foot ulcers and burn wounds.

Ulcer
Destiny Pharma Will Trial XF-73 In Diabetic Foot Ulcers And Burn Wounds • Source: Shutterstock

Destiny Pharma's CEO says that one year after listing on the London stock market, the antimicrobial specialist is on track to start the Phase IIb study of its lead asset for the prevention of post-surgical infections early next year and expects that to readout in the second half of 2019.

In an interview with Scrip, Neil Clark also said the group has enough money to then see it into the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.